Superparamagnetic iron oxide nanoparticles mediated 131I-hVEGF siRNA inhibits hepatocellular carcinoma tumor growth in nude mice

Abstract

BackgroundHepatocellular carcinoma (HCC) is a primary liver tumor and is the most difficult human malignancy to treat. In this study, we sought to develop an integrative approach in which real-time tumor monitoring, gene therapy, and internal radiotherapy can be performed simultaneously. This was achieved through targeting HCC with superparamagnetic iron oxide nanoparticles (SPIOs) carrying small interfering RNA with radiolabled iodine 131 (131I) against the human vascular endothelial growth factor (hVEGF).MethodshVEGF siRNA was labeled with 131I by the Bolton-Hunter method and conjugated to SilenceMag, a type of SPIOs. 131I-hVEGF siRNA/SilenceMag was then subcutaneously injected into nude mice with HCC tumors exposed to an external magnetic field (EMF). The biodistribution and cytotoxicity of 131I-hVEGF siRNA/SilenceMag was assessed by SPECT (Single-Photon Emission Computed Tomography) and MRI (Magnetic Resonance Imaging) studies and blood kinetics analysis. The body weight and tumor size of nude mice bearing HCC were measured daily for the 4-week duration of the experiment.Results131I-hVEGF siRNA/SilenceMag was successfully labeled; with a satisfactory radiochemical purity (>80%) and biological activity in vitro. External application of an EMF successfully attracted and retained more 131I-hVEGF siRNA/SilenceMag in HCC tumors as shown by SPECT, MRI and biodistribution studies. The tumors treated with 131I-hVEGF siRNA/SilenceMag grew nearly 50% slower in the presence of EMF than those without EMF and the control. Immunohistochemical assay confirmed that the tumor targeted by 131I-hVEGF siRNA/SilenceMag guided by an EMF had a lower VEGF protein level compared to that without EMF exposure and the control.ConclusionsEMF-guided 131I-hVEGF siRNA/SilenceMag exhibited an antitumor effect. The synergic therapy of 131I-hVEGF siRNA/SilenceMag might be a promising future treatment option against HCC with the dual functional properties of tumor therapy and imaging.

Emerging Nanotechnology and Advanced Materials for Cancer Radiation Therapy

“…[161] Different coatings of magnetite nanoparticles (e.g. [161] Different coatings of magnetite nanoparticles (e.g.…”

The possibility of using magnetic nanoparticles to increase the therapeutic efficiency of Herceptin antibody

“…The tumors treated with this complex grew nearly 50% slower in the presence of EMF than those without EMF and the control. The biodistribution analysis showed that the complex stayed in the bloodstream for a short time (t 1/2 = 2.22±0.17 h in the presence of EMF and 3.37±1.17 h in the absence of EMF) [3].…”

Effective photothermal chemotherapy with docetaxel-loaded gold nanospheres in advanced prostate cancer

“…Possible applications include (1) improved delivery of poorly water-soluble drugs, (2) site-directed delivery of drugs towards specific biological and molecular targets, (3) development of innovative diagnostic tools and (4) the combination of therapeutic agents with diagnostic probes [8][9][10][11]. Among all the types of inorganic nanoparticles, gold nanoparticles are the most widely used for drug delivery and other biological applications, due to their non-toxic and biocompatible properties, their size-and shape-controllable synthesis, the ease of surface modification with functional thiolate ligands and their extremely rich and versatile optical properties related to their surface plasmon band [12,13].…”

“…Nanoparticle drug delivery systems maximize the permeability and retention of drugs in solid tumors, and thus can reduce systemic toxicity and reverse drug resistance mechanisms by improving availability and activity at tumor sites [22,23]. During the last two decades, intensive research has focused on various nano-based approaches, but few types of nanoparticles have been utilized for DTX delivery [11,21]. Nanoparticle DTX delivery systems should have the following properties: (1) good solubility under physiological conditions, (2) good stability until the drug arrives at the target cancer cells, (3) selectivity and efficiency in targeting cancer cells, (4) slow release in cancer cells and (5) minimal side effects toward normal cells.…”